These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 24277175)
1. Raltegravir: a review of its use in the management of HIV-1 infection in children and adolescents. Perry CM Paediatr Drugs; 2014 Feb; 16(1):91-100. PubMed ID: 24277175 [TBL] [Abstract][Full Text] [Related]
2. Similar efficacy and tolerability of raltegravir-based antiretroviral therapy in HIV-infected patients, irrespective of age group, burden of comorbidities and concomitant medication: Real-life analysis of the German 'WIP' cohort. Naumann U; Moll A; Schleehauf D; Lutz T; Schmidt W; Jaeger H; Funke B; Witte V Int J STD AIDS; 2017 Aug; 28(9):893-901. PubMed ID: 28385065 [TBL] [Abstract][Full Text] [Related]
3. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. Markowitz M; Nguyen BY; Gotuzzo E; Mendo F; Ratanasuwan W; Kovacs C; Prada G; Morales-Ramirez JO; Crumpacker CS; Isaacs RD; Gilde LR; Wan H; Miller MD; Wenning LA; Teppler H; J Acquir Immune Defic Syndr; 2007 Oct; 46(2):125-33. PubMed ID: 17721395 [TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial. Nachman S; Alvero C; Teppler H; Homony B; Rodgers AJ; Graham BL; Fenton T; Frenkel LM; Browning RS; Hazra R; Wiznia AA; Lancet HIV; 2018 Dec; 5(12):e715-e722. PubMed ID: 30527329 [TBL] [Abstract][Full Text] [Related]
5. Raltegravir: in treatment-naive patients with HIV-1 infection. Croxtall JD; Scott LJ Drugs; 2010 Mar; 70(5):631-42. PubMed ID: 20329808 [TBL] [Abstract][Full Text] [Related]
6. Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients. Skiest DJ; Cohen C; Mounzer K; Haigney Z; Barker D; Gottlieb M; Bellman PC; Dejesus E; Khanlou H; Ruane PJ; Hsiao CB; Abriola K; Rashbaum B; Bellos N; Ward D; Colson A; Santiago F; Habel A; Garb J HIV Clin Trials; 2011; 12(3):131-40. PubMed ID: 21684853 [TBL] [Abstract][Full Text] [Related]
7. 96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience. Capetti A; Landonio S; Meraviglia P; Di Biagio A; Lo Caputo S; Sterrantino G; Ammassari A; Menzaghi B; Franzetti M; De Socio GV; Pellicanò G; Mazzotta E; Soria A; Meschiari M; Trezzi M; Sasset L; Celesia BM; Zucchi P; Melzi S; Ricci E; Rizzardini G PLoS One; 2012; 7(7):e39222. PubMed ID: 22808029 [TBL] [Abstract][Full Text] [Related]
8. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM; AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288 [TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study. Gatell JM; Katlama C; Grinsztejn B; Eron JJ; Lazzarin A; Vittecoq D; Gonzalez CJ; Danovich RM; Wan H; Zhao J; Meibohm AR; Strohmaier KM; Harvey CM; Isaacs RD; Nguyen BY; J Acquir Immune Defic Syndr; 2010 Apr; 53(4):456-63. PubMed ID: 20306554 [TBL] [Abstract][Full Text] [Related]
10. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Raffi F; Rachlis A; Stellbrink HJ; Hardy WD; Torti C; Orkin C; Bloch M; Podzamczer D; Pokrovsky V; Pulido F; Almond S; Margolis D; Brennan C; Min S; Lancet; 2013 Mar; 381(9868):735-43. PubMed ID: 23306000 [TBL] [Abstract][Full Text] [Related]
11. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results. Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. Gallien S; Braun J; Delaugerre C; Charreau I; Reynes J; Jeanblanc F; Verdon R; de Truchis P; May T; Madelaine-Chambrin I; Aboulker JP; Molina JM; J Antimicrob Chemother; 2011 Sep; 66(9):2099-106. PubMed ID: 21712241 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Molina JM; Lamarca A; Andrade-Villanueva J; Clotet B; Clumeck N; Liu YP; Zhong L; Margot N; Cheng AK; Chuck SL; Lancet Infect Dis; 2012 Jan; 12(1):27-35. PubMed ID: 22015077 [TBL] [Abstract][Full Text] [Related]
14. Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients. Croxtall JD; Keam SJ Drugs; 2009 May; 69(8):1059-75. PubMed ID: 19496631 [TBL] [Abstract][Full Text] [Related]
18. Successful integrase inhibitor-based highly active antiretroviral therapy for a multidrug-class-resistant HIV type 1 group O-infected patient in Cameroon. Aghokeng AF; Kouanfack C; Peeters M; Mpoudi-Ngole E; Delaporte E AIDS Res Hum Retroviruses; 2013 Jan; 29(1):1-3. PubMed ID: 22889147 [No Abstract] [Full Text] [Related]
19. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. da Silva D; Van Wesenbeeck L; Breilh D; Reigadas S; Anies G; Van Baelen K; Morlat P; Neau D; Dupon M; Wittkop L; Fleury H; Masquelier B J Antimicrob Chemother; 2010 Jun; 65(6):1262-9. PubMed ID: 20388636 [TBL] [Abstract][Full Text] [Related]